# PASO-DOBLE: Dovato vs Biktarvy Head-to-Head

**ID:** TRT-009
**Year:** 2024
**Source:** ViiV
**Link:** [https://viivhealthcare.com/en-us/media-center/news/press-releases/2024/july/viiv-healthcare-to-announce-data-from-largest-head-to-head-randomised/](https://viivhealthcare.com/en-us/media-center/news/press-releases/2024/july/viiv-healthcare-to-announce-data-from-largest-head-to-head-randomised/)

---

## Abstract

Largest head-to-head randomized trial comparing 2-drug Dovato vs 3-drug Biktarvy regimens.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
